Bryostatin-1: a novel PKC inhibitor in clinical development (Q35634829)

9 August 2017

1 reference

title

Bryostatin-1: a novel PKC inhibitor in clinical development (English)

1 reference

9 August 2017

1 reference

ChEBI release 2020-05-28

Jeremy Kortmansky

1

1 reference

PubMed ID

14735696

9 August 2017

Gary K Schwartz

series ordinal

2

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

21

1 reference

9 August 2017

924-936

1 reference

9 August 2017

6

1 reference

Protein kinase C targeting in antineoplastic treatment strategies

9 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

The extended protein kinase C superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Chemistry and clinical biology of the bryostatins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Evidence for protein kinase C-dependent and -independent activation of mitogen-activated protein kinase in T cells: potential role of additional diacylglycerol binding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Protective role of IL-2 during activation of T cells with bryostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

A phase II study of bryostatin 1 in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Phase II evaluation of bryostatin-1 in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin 1-activated T cells can traffic and mediate tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Bryostatin/ionomycin-activated T cells mediate regression of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

Biological activity of 26-succinylbryostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025095

21 January 2018

Identifiers

DOI

10.1081/CNV-120025095

1 reference

9 August 2017

1 reference

PubMed ID

14735696